Prandin (repaglinide), a new oral hypoglycemic for type 2 diabetes

You'll soon see Prandin (repaglinide), a new oral hypoglycemicfor type 2 diabetes...co-marketed by Novo Nordisk and Schering.

It's approved for monotherapy...and for use with metformin(Glucophage). It's also being tested with troglitazone (Rezulin).

Prandin is the first drug in a new class...the meglitinides.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote